Form 4: SAB Biotherapeutics CMO's Routine Tax Withholding

SAB Biotherapeutics' Chief Medical Officer, Alexandra Kropotova, reported a disposition of 1,977 shares for tax withholding related to RSU vesting.

Summary

• Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (SABS), reported a transaction on September 19, 2025.
• The transaction involved the disposition of 1,977 shares of Common Stock.
• These shares were withheld to satisfy tax withholding requirements upon the vesting of the Issuer's restricted stock units (RSUs).
• Following this transaction, Ms. Kropotova beneficially owns 45,272 shares of Common Stock.
• This beneficial ownership includes 29,340 shares of Common Stock and 15,932 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event related to RSU vesting, which is a neutral operational event for the company and the insider, reflecting standard executive compensation practices.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued equity compensation for the Chief Medical Officer, aligning her interests with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction related to executive compensation.
• Chief Medical Officer: Continues to hold significant equity in the company, aligning her interests with long-term company performance.

Key Dates

Keywords

SAB Biotherapeutics, SABS, Alexandra Kropotova, Form 4, insider transaction, RSU vesting, tax withholding, Chief Medical Officer